Treating amyotrophic lateral sclerosis with a bone marrow derived mesenchymal stem cell extracellular vesicles - A case report

Joshua James Crose *

Capitis Medical & Aesthetics, Inc., 1917 Douglas Blvd. Ste. 89, Roseville, Ca. 95661.
 
Review
International Journal of Science and Research Archive, 2021, 02(02), 167–171.
Article DOI: 10.30574/ijsra.2021.2.2.0058
Publication history: 
Received on 27 April 2021; revised on 16 May 2021; accepted on 19 May 2021
 
Abstract: 
Amyotrophic Lateral Sclerosis (ALS) is a terminal neurodegenerative disease with only a few minimally effective treatment options.  This study treats a patient with Spinal ALS with Bone Marrow Derived Mesenchymal Stem Cell Extracellular Vesicles (BM-MSCEVs) to slow or stop the progress of the disease.  After 2 months and 4 treatments, the patient demonstrated improvement in ALS functional scores and most physical exam findings. BM-MSCEVs demonstrate the ability to effectively treat Spinal ALS in this study and open the door for future studies.
 
Keywords: 
Mesenchymal Stem Cells; Extracellular Vesicles; Exosomes; Amyotrophic Lateral Sclerosis; ALS; Bone Marrow
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0